Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 mai 2026 16h30 HE | Source: Cellectis Inc.

Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
20 mai 2026 16h30 HE | Source: Cellectis Inc.

L’Assemblée Générale Mixte de Cellectis se tiendra le le 25 juin 2026

NEW YORK, 20 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour...
20 mai 2026 08h05 HE | Source: Totaligent

Totaligent Closes Strategic Acqui-Hire of Aetherium Medical Platform

Totaligent (OTCID:TGNT) successfully closed the strategic acqui-hire of the Aetherium Medical platform and team.
20 mai 2026 08h00 HE | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research...
20 mai 2026 08h00 HE | Source: Madrigal Pharmaceuticals, Inc.

Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk

Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB with Rezdiffra® (resmetirom)Analysis of two-year data in...
20 mai 2026 07h35 HE | Source: Kraig Biocraft Laboratories

Kraig Biocraft Laboratories Highlights Technical Breakthrough of Its Immortalized Silk Gland Cell Platform

Kraig Labs (OTCQB: KBLB) provides additional details regarding the significant advantages of its newly developed immortalized silk gland cell platform
20 mai 2026 01h30 HE | Source: Synendos Therapeutics AG

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population
19 mai 2026 10h28 HE | Source: 24/7 Market News and NeOnc Technology

NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones

Wall St analysts are rating NeOnc Technologies (NASDAQ:NTHI) a “Buy”, as institutional investors and company insiders are buying
19 mai 2026 09h15 HE | Source: Edesa Biotech, Inc.

Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA),...
19 mai 2026 08h30 HE | Source: Seegnal Inc.

Seegnal Announces Letter of Intent with U.S.-Based Care Facility, Marking First Penetration of the American Healthcare Market

CALGARY, AB, May 19, 2026 (GLOBE NEWSWIRE) -- Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a developer of innovative healthcare technology focused on mitigating medication risks, today...

Page suivante